Status:
WITHDRAWN
Intra-lesional ACE Inhibitor for Treatment of Hypertrophic Scars
Lead Sponsor:
Nova Scotia Health Authority
Conditions:
Hypertrophic Scar
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Hypertrophic scarring is a difficult and debilitating condition where one develops excessive scarring after full thickness injury to the skin. This is very common in full thickness burn injury. Curren...
Detailed Description
Intralesional injection of corticosteroids such as triamcinolone acetonide (TAC) for treatment of hypertrophic scars are often used as first-line therapy owing to their ease of administration and rela...
Eligibility Criteria
Inclusion
- Patients with scar tissue demonstrating features of hypertrophic scarring (e.g., raised, red tissue, contractures, extends beyond the boundary of the original wound)
Exclusion
- scar does not demonstrate any distinguishing features of hypertrophic scar;
- self-reported as pregnant and/or breastfeeding;
- documented hepatic, heart, or renal dysfunction;
- patients with known Cushing's disease or glaucoma;
- documented history of angioedema;
- patients with diabetes;
- patients being treated with any anti-hypertensive medications
- patients under 18 years of age
Key Trial Info
Start Date :
August 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2026
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05259137
Start Date
August 1 2024
End Date
October 1 2026
Last Update
February 17 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.